Molecular profile of advanced-stage transitional cell carcinoma of the ovary

American Journal of Obstetrics and Gynecology

Volumn 177, Issue 1, 1997, Pages 120-125

  Gershenson, D M ^a   Baker, V V ^a   Price, J E ^a   Hung, M C ^a   El Naggar, A K ^a   Tortolero Luna, G ^a   Silva, E G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Deoxyribonucleic acid ploidy; Epidermal growth factor receptor; HER 2 neu; P53; Platinum based chemotherapy; Transitional cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IFOSFAMIDE; MELPHALAN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY CANCER; OVARY CARCINOMA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

EID: 0030872038     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(97)70449-6     Document Type: Article

References (31)

1. RM Austin HJ. Norris Malignant Brenner tumor and transitional cell carcinoma of the ovary: a comparison Int J Gynecol Pathol 6 1987 29 39
2. SS Robey EG Silva DM Gershenson D McLemore A El-Naggar NG. Ordonez Transitional cell carcinoma in high-grade, high-stage ovarian carcinoma Cancer 63 1989 839 847
3. EG Silva SS Robey-Cafferty TL Smith DM. Gershenson Ovarian carcinomas with transitional cell carcinoma pattern Am J Clin Pathol 93 1990 457 465
4. DM Gershenson EG Silva MF Mitchell EN Atkinson JT. Wharton Transitional cell carcinoma of the ovary: a matched control study of advanced stage patients treated with cisplatin-based chemotherapy Am J Obstet Gynecol 168 1993 1178 1187
5. KM Sweeten DM Gershenson TW Burke M Morris C Levenback EG. Silva Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC) Gynecol Oncol 59 1995 211 215
6. CJ Rodenburg CJ Comelisse J Hermann GJ. Fleuren DNA flow cytometry and morphometry as prognostic indicators in advanced ovarian cancer: a step forward in predicting the clinical outcome Gynecol Oncol 29 1988 176 187
7. ML Friedlander DW Hedley C Swanson P. Russell Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer J Clin Oncol 6 1988 282 290
8. PJ Klemi H Joensuu J Mäenpää P. Kiilholma Influence of cellular DNA content on survival in ovarian carcinoma Obstet Gynecol 74 1989 200 204
9. JR Marks AM Davidoff B Kems Overexpression and mutation of p53 in epithelial ovarian cancer Cancer Res 51 1991 2979 2984
10. A Berchuck MF Kohler JR Marks R Wiseman J Boyd RC. Bast The p53 tumor suppressor gene frequently is altered in gynecologic cancers Am J Obstet Gynecol 170 1994 246 252
11. T Kihana H Tsuda S Teshima S Okada S Matsuura S. Hirohashi High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and DNA aneuploidy J Cancer Res 83 1992 978 984
12. A Berchuck A Kamel R Whitaker Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 1990 4087 4091
13. DJ Slamon W Godolphin LA Jones Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
14. A Berchuck GC Rodriguez A Kamel Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer, I: correlation of receptor expression with prognostic factors in patients with ovarian cancer Am J Obstet Gynecol 164 1991 669 674
15. G Scambia PB Panici F Battaglia Significance of epidermal growth factor receptor in advanced ovarian cancer J Clin Oncol 10 1992 529 535
16. DW Hedley ML Friedlander IW. Taylor Method for analysis of cellular DNA content of paraffin-embedded pathological materials using flow cytometry J Histochem Cytochem 31 1983 1333 1335
17. DD McLemore AK El-Naggar LC Stephens J. Jardine Modified methodology to improve flow cytometric DNA histograms from paraffin-embedded material Stain Technology 65 1990 279 291
18. DA Johnston RA White B. Barlogie Antomated processing and interpretation of DNA distributions: comparison of several techniques Comput Biomed Res 11 1978 393 404
19. B Barlogie W Göhde DA. Johnston Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry Cancer Res 38 1978 3333 3339
20. H Baisch W Göhde WA. Linden Analysis of PCP-data to determine the fraction of cells in the various phases of cells cycle Radiat Environ Biophys 12 1975 31 39
21. GN Gill W Weber DM Thompson Relationship between production of epidermal growth factor receptors, gene amplification, and chromosome 7 translocation in variant A431 cells Somat Cell Mol Genet 11 1985 309 318
22. SM Hsu L Raine H. Fanger The use of avidin-botin-peroxidase complex (ABC) in immunoperoxldase technique: a comparison between ABC and unlabeled antibody (PAP) procedures J Histochem Cytochem 29 1982 577 580
23. SPSS, Inc SPSS reference guide 1990 SPSS Chicago
24. EL Kaplan P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
25. V Seltzer S Vogl B. Kaplan Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent Gynecol Oncol 21 1985 167 176
26. DM Gershenson JJ Kavanagh LJ Copeland CA Stringer M Morris JT. Wharton Retreatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy Obstet Gynecol 73 1989 798 802
27. ME Gore I Fryatt E Wiltshaw T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
28. M Markman R Rothman T Hakes Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
29. O Stal M Dufmats T Hatschek S phase fraction is a prognostic factor in stage I breast carcinoma J Clin Oncol 11 1993 1717 1722
30. JS Haldane V Hird CM Hughes WJ. Gullick c- erbB -2 oncogene expression in ovarian cancer J Pathol 162 1990 231 237
31. SC Rubin CL Finstad GY Wong L Almadrones M Plante KO. Lloyd Prognostic significance of HER-2/ neu expression in advanced epithelial ovarian cancer: a multivariate analysis Am J Obstet Gynecol 168 1993 162 169